Tuesday, November 17, 2026

Hyundai Bioscience Receives Approval for Therapeutic Use of Prostate Cancer Drug Candidate 'Penetrium'

Input
2026-11-17 08:59:14
Updated
2026-11-17 09:28:47
[Financial News] Hyundai Bioscience has opened the way for a patient participating in a clinical trial of a prostate cancer drug candidate to continue treatment. The Ministry of Food and Drug Safety (MFDS) approved additional use so that a patient who completed the prescribed dosing period in a Phase 1 trial could continue combination treatment with existing anticancer drugs.
Hyundai Bioscience said on the 17th that the MFDS had approved therapeutic use of its anticancer drug candidate Penetrium (CP-PCA07) for the first patient to participate in a Phase 1 trial for castration-resistant prostate cancer.
The patient has metastatic castration-resistant prostate cancer (mCRPC) that progressed after previous hormone therapy. Beginning in August, the patient received the minimum dose of Penetrium, 600 mg per day (three 200-mg tablets), together with the existing prostate cancer treatment enzalutamide. The patient completed 12 weeks of clinical trial dosing on the 2nd. Professor Jung Chang-wook, the patient's attending physician in the Department of Urology at Seoul National University Hospital (SNUH), applied for additional use after comprehensively considering the patient's overall condition, expected tolerability and treatment response observed during the trial, given that the patient would have difficulty undergoing cytotoxic chemotherapy such as docetaxel.
The MFDS approved the therapeutic-use application Professor Jung submitted on the 6th on the 16th, just 10 days later. The expected duration of use is six months. Hyundai Bioscience plans to provide the patient with 180 days' worth of the drug (1,080 tablets) free of charge and support safety follow-up and related reporting in collaboration with the medical team.
Penetrium is a drug candidate under development based on the observation that the tumor microenvironment surrounding cancer cells can interfere with the action of anticancer drugs. It aims to enhance the therapeutic effects of existing anticancer drugs by easing barriers formed by cancer-associated fibroblasts (CAFs), the extracellular matrix (ECM) and other factors.
Hyundai Bioscience is conducting a Phase 1 clinical trial for prostate cancer in South Korea, and in September it received notification from the U.S. Food and Drug Administration (FDA) that it could proceed with a Phase 2a trial for relapsed, refractory, advanced solid tumors.

[email protected] Jung Sang-hee Reporter